ProfoundBio US Co.
🇺🇸United States
PRO1160 for Advanced Solid and Liquid Tumors (PRO1160-001)
Phase 1
Recruiting
- Conditions
- Renal Cell CarcinomaNasopharyngeal CarcinomaNon Hodgkin Lymphoma
- Interventions
- First Posted Date
- 2023-02-09
- Last Posted Date
- 2024-08-13
- Lead Sponsor
- ProfoundBio US Co.
- Target Recruit Count
- 134
- Registration Number
- NCT05721222
- Locations
- 🇨🇳
Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, Shanghai, China
🇺🇸City of Hope Comprehensive Cancer Center - Duarte, Duarte, California, United States
🇺🇸Washington University School of Medicine in St. Louis, Saint Louis, Missouri, United States
Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
Phase 1
Recruiting
- Conditions
- High Grade Epithelial Ovarian CancerHigh Grade Serous Ovarian CancerPrimary Peritoneal CarcinomaFallopian Tube CancerEndometrial CancerNon-small Cell Lung CancerEpidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer (NSCLC)MesotheliomaBreast AdenocarcinomaTriple Negative Breast Cancer
- Interventions
- First Posted Date
- 2022-10-13
- Last Posted Date
- 2025-05-06
- Lead Sponsor
- ProfoundBio US Co.
- Target Recruit Count
- 529
- Registration Number
- NCT05579366
- Locations
- 🇺🇸
University of California Los Angeles Medical Center, Los Angeles, California, United States
🇺🇸USOR HonorHealth, Phoenix, Arizona, United States
🇺🇸USOR Arizona Oncology Associates, Tucson, Arizona, United States
© Copyright 2025. All Rights Reserved by MedPath